<DOC>
	<DOCNO>NCT00613054</DOCNO>
	<brief_summary>Primary Objective To determine maximum tolerate dose &amp; dose limiting toxicity Zactima combine w standard dose imatinib mesylate &amp; hydroxyurea among pt w recurrent malignant glioma &amp; enzyme-inducing anti-epileptic drug Secondary Objectives To assess safety &amp; tolerability Zactima + imatinib mesylate &amp; hydroxyurea To evaluate pharmacokinetics Zactima among MG pt &amp; enzyme induce anti-epileptic drug ( EIAEDs ) combo w imatinib mesylate &amp; hydroxyurea To evaluate pharmacokinetics imatinib mesylate among MG pt &amp; EIAEDs combo w Zactima &amp; hydroxyurea Exploratory Objective To evaluate evidence anti-tumor activity study regimen among recurrent malignant glioma ( RMG ) pts include radiographic response rate , 6-month progression free survival ( PFS ) rate &amp; median PFS</brief_summary>
	<brief_title>Ph I Zactima + Imatinib Mesylate &amp; Hydroxyurea Pts w Recurrent Malignant Glioma</brief_title>
	<detailed_description>vascular endothelial growth factor ( VEGF ) angiogenic &amp; Phosphoinositide 3-kinase inhibitor/Protein Kinase B ( PI3K/AKT ) mitogenic cascade 2 upregulated cell signal pathway MG contribute several hallmark phenotypic feature tumor . Regimen Zactima + imatinib mesylate represent novel anti-glioma strategy target 3 key mediator dysregulated cell signal involve VEGF &amp; PI3K-AKT pathways include VEGFR , epidermal growth factor receptor ( EGFR ) &amp; platelet derive growth factor ( PDGFR ) . Furthermore combine Zactima w imatinib mesylate , VEGF &amp; PI3-k/AKT pathways potentially inhibit multiple mediator pathway . Regarding PI3-K/AKT signalling , regimen inhibit activation EGFR &amp; PDGFR . Regarding VEGF signalling , regimen potential inhibit 3 component VEGFR direct angiogenesis . 1st , Zactima directly inhibit VEGFR activation . 2nd , Zactima &amp; imatinib mesylate indirectly decrease activity VEGF pathway diminish positive input activate PI3-K/AKT signalling . 3rd , imatinib mesylate may inhibit PDGF-regulated pericyte maturation tumor blood vessel . We previously demonstrate regimen imatinib mesylate + hydroxyurea active regimen among recurrent glioblastoma multiforme ( GBM ) pt . Furthermore activity appear substantially well report imatinib mesylate alone . Although mechanism enhance activity imatinib mesylate combo w hydroxyurea unclear , logical build upon combo imatinib mesylate + hydroxyurea subsequent study rather imatinib mesylate alone . Current study therefore determine MTD Zactima combo w standard dose imatinib mesylate &amp; hydroxyurea among RMG pt . Ph II study perform , incorporate maximum tolerate dose ( MTD ) Zactima + imatinib mesylate order evaluate anti-glioma potential regimen .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Pts baseline evaluation perform ≤14days prior 1st dose study drug unless otherwise specify . Written informed consent must obtain pt prior enrollment Pts w MG present 1st , 2nd 3rd recurrence relapse Pts may tumor biopsy &lt; 1 wk surgical resection &lt; 2wks For stratum nonEIAED pt , pt EIAEDs &gt; 2 wks prior start study drug ; similarly stratum EIAED pt , pt EIAED &gt; 2 wks prior start study drug Pts nonincreasing dose steroid &gt; 7 day prior obtain baseline GdMRI brain Pts nonincreasing dose steroid &gt; 7 day prior start study drug Multifocal disease eligible Age &gt; 18yrs Karnofsky Performance Status ( KPS ) &gt; 70 Absolute neutrophil count ( ANC ) &gt; 1.0 x 10 9/L Hgb &gt; g/dL Platelets &gt; 100 x 10 9/L Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) /measured 24hr creatinine clearance ( CrCl ) &gt; 50 milliliters/min/1.73m Life ≥12wks Written inform consent obtain prior screen procedure Serum bilirubin &gt; 1.5x ULN reference range Serum creatinine &gt; 1.5 x Upper Limit Reference Range ( ULRR ) /CrCl &lt; 50 milliliters/min K &lt; 4.0 mmol/L despite supplementation ; serum Ca/Mg normal range despite supplementation alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 x ULRR Evidence severe/uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable pt participate trial would jeopardize compliance w protocol Clinically significant cardiac event myocardial infarction ; New York Heart Association ( NYHA ) classification heart disease &gt; 2 within 3 month entry ; /presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia dysfunction ; ejection fraction &lt; 50 percent prior study initiation History arrhythmiasymptomatic/requires treatment/asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication exclude Previous history correct QT interval ( QTc ) prolongation result medication require discontinuation medication Congenital long QT syndrome/1st degree relative unexplained sudden death 40 year Presence leave bundle branch block QTc Bazett 's correction unmeasurable/ &gt; 480 msec screen ECG . If pt QTc &gt; 480 msec screen ECG , screen ECG may repeat twice . Average QTc 3 screen ECGs must &lt; 480 msec order pt eligible study Any concomitant medication may cause QTc prolongation , induce Torsades de Pointes/induce cytochrome P450 3A4 ( CYP3A4 ) function except EIAEDs Hypertension control medical therapy Currently active diarrhea may affect ability pt absorb study regimen/tolerate diarrhea Pregnant/breast feeding Previous/current malignancy histologies &lt; 1yr , w exception cervical carcinoma situ &amp; adequately treat basal cell/squamous cell carcinoma skin Receipt investigational agent within 30 day prior commence study treatment unless pt recover anticipated toxicity investigational agent Last dose prior chemo discontinue &lt; 4 wks start study therapy unless pt recover anticipated toxicity chemo Last radiation therapy ( XRT ) &lt; 4wks start study therapy , unless pt recover anticipated toxicity XRT Any unresolved toxicity &gt; Common Terminology Criteria ( CTC ) grade 1 previous anticancer therapy Previous enrollment/randomization treatment present study Major surgery &lt; 4 wks/incompletely heal surgical incision start study therapy Pts receive prior oral VEGFR , EGFR/PDGFRdirected therapies Pts take warfarin sodium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Zactima</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Recurrent malignant glioma</keyword>
	<keyword>ZD6474</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Droxia</keyword>
	<keyword>Hydrea</keyword>
	<keyword>Hydroxycarbamide</keyword>
	<keyword>Vandetanib</keyword>
</DOC>